Home > Pulmonology > ATS 2022 > POISE-3: Tranexamic acid for non-cardiac surgery

POISE-3: Tranexamic acid for non-cardiac surgery

Presented By
Prof. Philip Devereaux, McMaster University, Canada
Conference
ATS 2022
Trial
Phase 3, POISE-3
The POISE-3 clinical trial compared the use of antifibrinolytic tranexamic acid with placebo and investigated the effect of managing hypotension versus standard of care (i.e. hypertension) in patients undergoing non-cardiac surgery who are at risk of a peri-operative cardiovascular event. The efficacy endpoint favours a wider use of tranexamic acid at the start and end of non-cardiac surgery. Although the difference in composite cardiovascular complications between the tranexamic acid group and the placebo group was small, the non-inferiority of tranexamic acid was not established, making it a new option for patients. Prof. Philip Devereaux (McMaster University, Canada) presented the international, multicentre, randomised POISE-3 study (NCT03505723) during the late...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on